Developer docs
API playgroundTry for free, no card

Search company profiles

Cordlife

Full company profile

uuid003e3qs

Namestring
Cordlife
Legal namestring
Cordlife Group Limited
Websiteurl
cordlife.com
Company typeenum
Public
Founded yearint
2001
Descriptiontext

Cordlife Group Limited is a Singapore-headquartered, Mainboard-listed (SGX, since 2012) consumer healthcare company founded in May 2001 that pioneered private cord-blood banking in Asia. Its core offering is the collection, processing, and long-term cryogenic storage of umbilical cord blood and cord lining stem cells — a one-time, biological-insurance product collected at birth and held under multi-decade storage contracts. The company operates what it describes as Asia's largest network of cord blood banks, with six full stem cell banking facilities across Singapore, Hong Kong, India, Malaysia, Indonesia, and the Philippines, plus market presence in Vietnam and Myanmar and an indirect Thai stake via subsidiary Stemlife Berhad. Over 600,000 parents in Asia have entrusted Cordlife with samples, and 85+ cord-blood units have been released to 25 healthcare institutions in 10 countries for transplant or cellular therapy.

Beyond stem-cell banking, Cordlife provides a suite of diagnostics services aimed at expectant mothers and newborns: non-invasive prenatal testing (NIPT), paediatric vision screening, and newborn metabolic screening. The Cordlife Care 360° add-on package layers financial-assurance and insurance coverage (transplant cost coverage up to S$50,000, worldwide delivery, parental death/disability support, viable match guarantees, pre-transplant testing, professional indemnity, and pregnancy complication coverage) on top of core storage. The technology backbone centres on proprietary cryopreservation and Cordlife's CellOptima cord lining platform, supported by an Enhanced Lab Monitoring System with 24/7 real-time on-site and remote surveillance.

The go-to-market is a direct-to-consumer, sales-led model. Expectant parents enroll via a customer hotline, online enquiry, or physical/virtual consultation; the company then operates hospital collection partnerships across major Singapore providers (KKH, SGH, NUH, Mount Elizabeth, Gleneagles, Raffles, Thomson Medical, Mount Alvernia, Parkway East) and drives top-of-funnel awareness through education-led content, social media, baby fairs, and antenatal talks. Revenue is generated via one-time collection and processing fees plus recurring annual storage fees, with Child Development Account (CDA) payment accepted in Singapore. As of October 2025 Singapore's Ministry of Health imposed a potential one-year suspension following compliance failures, and on 14 January 2026 Cordlife received a restricted one-year licence renewal that prohibits new collection, testing, or storage of cord-blood units in Singapore — limiting operations to storage, transfer, and retrieval of existing units; the group is also facing civil claims of at least S$5.45 million for 109 allegedly damaged units and an FY2025 disclaimer of audit opinion from PKF-CAP.

Short descriptiontext

Cordlife Group Limited operates Asia's largest network of private cord-blood and cord lining stem cell banks across 10 markets, serving over 600,000 families with cryogenic storage, diagnostic services, and the Cordlife Care 360° protection package.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cord blood banking, stem cell cryopreservation, cord lining banking, prenatal diagnostic services, newborn screening services
Industry1 code
1Cell & Tissue Banking (biobanking, cord blood/tissue)
CodeHLAAAGAEPrimaryYes
NAICS code1 code
  • Blood and Organ Banks621991
Product category
Stem Cell Banking Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Cord Blood Banking Services
TypeSubscription Recurring
Description

One-time collection and processing fee plus annual storage fees for long-term cryopreservation of cord blood stem cells. Parents pay for banking services with options to pay using Child Development Account (CDA).

cordlife.com
2Cord Lining/Tissue Banking
TypeSubscription Recurring
Description

Collection, processing and storage services for cord lining stem cells, provided on research/clinical trial basis

cordlife.com
3Diagnostics Services
TypeSubscription Recurring
Description

Non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening services

cordlife.com:443
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Infrastructure, Operations, Personnel, Marketing or Sales, Technology or R&D
Pricing details1 tier
1Cord blood banking service with multiple coverage benefits
ModelSubscriptionBilling cadenceAnnual
Notes

Annual storage fees; collection and processing fees apply. Payment options include CDA. Cordlife Care 360° benefits package included with various coverage tiers.

cordlife.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Cordlife provides private cord blood and cord lining/tissue stem cell banking services, collecting, processing, and cryogenically storing umbilical cord stem cells for potential future medical use. It also offers diagnostic services such as non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening for expectant families.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 600,000 parents in Asia trust Cordlife for cord blood banking
+2 more records
Product overview1 text field

Cordlife is a consumer healthcare company offering a comprehensive suite of stem cell banking and diagnostic services for mothers and children. The core product portfolio centers on cord blood and cord lining stem cell collection, processing, and cryogenic storage services. Beyond stem cell banking, the company provides diagnostic services including non-invasive prenatal testing (NIPT), paediatric vision screening, and newborn metabolic screening. The Cordlife Care 360° add-on package offers comprehensive protection including hospital bill coverage, global cord blood delivery, financial support for parental death/disability, viable match guarantees, and pregnancy complication coverage. The company operates through its subsidiaries including Cordlife Technologies Pte Ltd for cord lining/tissue banking services.

Product and service7 records
1Cord Blood Stem Cells Storage
CategoryCord Blood Banking
Description

Collection, processing, and cryogenic storage of umbilical cord blood stem cells for potential future medical treatments. Cord blood can be used to treat over 80 diseases including blood cancers, immune disorders, and genetic disorders. For expectant parents choosing private/family banking.

2Cord Lining Stem Cells Storage
CategoryCord Lining Banking
Description

Collection, processing and cryogenic storage of umbilical cord lining stem cells with potential applications in regenerative medicine, provided on a research/clinical trial basis with proprietary CellOptima assurances.

3Cordlife Care 360°
CategoryProtection Package
Description

Comprehensive protection package for banking clients offering hospital bill coverage (TransplantCare up to S$50,000), global cord blood delivery (Worldwide), financial support for parent death/disability (Protect), viable cord blood match guarantee (Pledge), pre-transplant testing coverage (Assure), professional indemnity insurance (Guard), and pregnancy complication coverage (Shield).

4Non-Invasive Prenatal Testing (NIPT)
CategoryDiagnostics Service
Description

Prenatal diagnostic service offered as part of Cordlife's comprehensive suite of diagnostics services for expectant mothers.

5Paediatric Vision Screening
CategoryDiagnostics Service
Description

Paediatric vision screening service for children offered as part of Cordlife's comprehensive suite of diagnostics services.

6Newborn Metabolic Screening
CategoryDiagnostics Service
Description

Newborn metabolic screening service for early detection of metabolic conditions, offered as part of Cordlife's diagnostics suite.

7Cordlife Circle
CategoryLoyalty Program
Description

Loyalty program for existing Cordlife customers providing exclusive benefits and rewards.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Majority-owned subsidiary of Cordlife Group. Provides full stem cell banking services in Malaysia. Through this subsidiary, Cordlife has an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife.

2Thai Stemlife (Thailand)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Thailand's largest private cord blood bank. Cordlife has an indirect stake through its majority-owned subsidiary Stemlife Berhad in Malaysia.

cordlife.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

UK-based private cord blood and tissue bank offering comparable collection, processing, and cryogenic storage services with a multi-country footprint.

TypeDirect peer
Description

European-headquartered stem cell bank offering cord blood, cord tissue, and related banking services to families globally; closely comparable processing, storage, and consumer sales motion.

TypeDirect peer
Description

Cordlife's own majority-owned Malaysian subsidiary offering cord blood banking in Malaysia and Thailand (via Thai Stemlife) — a directly comparable private banking network in adjacent ASEAN markets.

TypeDirect peer
Description

US-based hybrid public-private cord blood bank providing both family banking and public registry services; comparable cryopreservation technology and clinical release track record.

TypeDirect peer
Description

Pan-Asian private cord blood bank with presence in Thailand, Singapore, India and other Asian markets; competes head-to-head with Cordlife for the same expectant-parent segment.

TypeBroad incumbent
Description

US-listed (NASDAQ: CCEL) cord blood and menstrual blood stem cell bank serving expectant parents; directly comparable business model of private/family cord blood banking with recurring storage revenue.

TypeBroad incumbent
Description

One of the largest US private cord blood banks operated by Revvity; comparable consumer healthcare service targeting expectant parents with one-time processing plus annual storage fees.

TypeBroad incumbent
Description

Long-established US private family cord blood bank under CooperSurgical (CooperCompanies); the clearest Western counterpart in scale, brand tenure, and stored-sample base.

TypeRegional player
Description

Non-profit public cord blood bank in Singapore; competes in the same Singapore market with a public-registry rather than private-storage model.

TypeRegional player
Description

Listed under Cordlife's Hong Kong navigation, HealthBaby is a major competing private cord blood bank in Hong Kong with overlapping expectant-parent customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cordlife

Stem Cell Banking Servicescordlife.com

Cordlife Group Limited operates Asia's largest network of private cord-blood and cord lining stem cell banks across 10 markets, serving over 600,000 families with cryogenic storage, diagnostic services, and the Cordlife Care 360° protection package.

What Cordlife does

Cordlife Group Limited is a Singapore-headquartered, Mainboard-listed (SGX, since 2012) consumer healthcare company founded in May 2001 that pioneered private cord-blood banking in Asia. Its core offering is the collection, processing, and long-term cryogenic storage of umbilical cord blood and cord lining stem cells — a one-time, biological-insurance product collected at birth and held under multi-decade storage contracts. The company operates what it describes as Asia's largest network of cord blood banks, with six full stem cell banking facilities across Singapore, Hong Kong, India, Malaysia, Indonesia, and the Philippines, plus market presence in Vietnam and Myanmar and an indirect Thai stake via subsidiary Stemlife Berhad. Over 600,000 parents in Asia have entrusted Cordlife with samples, and 85+ cord-blood units have been released to 25 healthcare institutions in 10 countries for transplant or cellular therapy.

Beyond stem-cell banking, Cordlife provides a suite of diagnostics services aimed at expectant mothers and newborns: non-invasive prenatal testing (NIPT), paediatric vision screening, and newborn metabolic screening. The Cordlife Care 360° add-on package layers financial-assurance and insurance coverage (transplant cost coverage up to S$50,000, worldwide delivery, parental death/disability support, viable match guarantees, pre-transplant testing, professional indemnity, and pregnancy complication coverage) on top of core storage. The technology backbone centres on proprietary cryopreservation and Cordlife's CellOptima cord lining platform, supported by an Enhanced Lab Monitoring System with 24/7 real-time on-site and remote surveillance.

The go-to-market is a direct-to-consumer, sales-led model. Expectant parents enroll via a customer hotline, online enquiry, or physical/virtual consultation; the company then operates hospital collection partnerships across major Singapore providers (KKH, SGH, NUH, Mount Elizabeth, Gleneagles, Raffles, Thomson Medical, Mount Alvernia, Parkway East) and drives top-of-funnel awareness through education-led content, social media, baby fairs, and antenatal talks. Revenue is generated via one-time collection and processing fees plus recurring annual storage fees, with Child Development Account (CDA) payment accepted in Singapore. As of October 2025 Singapore's Ministry of Health imposed a potential one-year suspension following compliance failures, and on 14 January 2026 Cordlife received a restricted one-year licence renewal that prohibits new collection, testing, or storage of cord-blood units in Singapore — limiting operations to storage, transfer, and retrieval of existing units; the group is also facing civil claims of at least S$5.45 million for 109 allegedly damaged units and an FY2025 disclaimer of audit opinion from PKF-CAP.

Cordlife firmographics

Firmographics
Name
Cordlife
Legal name
Cordlife Group Limited
Website
https://cordlife.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Short description
Cordlife Group Limited operates Asia's largest network of private cord-blood and cord lining stem cell banks across 10 markets, serving over 600,000 families with cryogenic storage, diagnostic services, and the Cordlife Care 360° protection package.
Ownership category
akta.pro rank

Cordlife industry classification

Industry
Product category
Stem Cell Banking Services
NAICS
Blood and Organ Banks (621991)
akta.pro primary industry
Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

Keywords

  • Cord blood banking
  • Stem cell cryopreservation
  • Cord lining banking
  • Prenatal diagnostic services
  • Newborn screening services

Where Cordlife is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices8 records

Markets served

Cordlife business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Infrastructure, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Cord Blood Banking Services: One-time collection and processing fee plus annual storage fees for long-term cryopreservation of cord blood stem cells. Parents pay for banking services with options to pay using Child Development Account (CDA).
  2. Cord Lining/Tissue Banking: Collection, processing and storage services for cord lining stem cells, provided on research/clinical trial basis
  3. Diagnostics Services: Non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening services

Pricing tiers

ModelBillingPrice
SubscriptionAnnualCord blood banking service with multiple coverage benefits

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Cordlife product offering

Product offering

Core offering

Cordlife provides private cord blood and cord lining/tissue stem cell banking services, collecting, processing, and cryogenically storing umbilical cord stem cells for potential future medical use. It also offers diagnostic services such as non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening for expectant families.

Product overview

Cordlife is a consumer healthcare company offering a comprehensive suite of stem cell banking and diagnostic services for mothers and children. The core product portfolio centers on cord blood and cord lining stem cell collection, processing, and cryogenic storage services. Beyond stem cell banking, the company provides diagnostic services including non-invasive prenatal testing (NIPT), paediatric vision screening, and newborn metabolic screening. The Cordlife Care 360° add-on package offers comprehensive protection including hospital bill coverage, global cord blood delivery, financial support for parental death/disability, viable match guarantees, and pregnancy complication coverage. The company operates through its subsidiaries including Cordlife Technologies Pte Ltd for cord lining/tissue banking services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cord Blood Stem Cells Storage Collection, processing, and cryogenic storage of umbilical cord blood stem cells for potential future medical treatments. Cord blood can be used to treat over 80 diseases including blood cancers, immune disorders, and genetic disorders. For expectant parents choosing private/family banking.
  • Cord Lining Stem Cells Storage Collection, processing and cryogenic storage of umbilical cord lining stem cells with potential applications in regenerative medicine, provided on a research/clinical trial basis with proprietary CellOptima assurances.
  • Cordlife Care 360° Comprehensive protection package for banking clients offering hospital bill coverage (TransplantCare up to S$50,000), global cord blood delivery (Worldwide), financial support for parent death/disability (Protect), viable cord blood match guarantee (Pledge), pre-transplant testing coverage (Assure), professional indemnity insurance (Guard), and pregnancy complication coverage (Shield).
  • Non-Invasive Prenatal Testing (NIPT) Prenatal diagnostic service offered as part of Cordlife's comprehensive suite of diagnostics services for expectant mothers.
  • Paediatric Vision Screening Paediatric vision screening service for children offered as part of Cordlife's comprehensive suite of diagnostics services.
  • Newborn Metabolic Screening Newborn metabolic screening service for early detection of metabolic conditions, offered as part of Cordlife's diagnostics suite.
  • Cordlife Circle Loyalty program for existing Cordlife customers providing exclusive benefits and rewards.

Quantifiable outcome

  • Over 600,000 parents in Asia trust Cordlife for cord blood banking
  • +2 more outcomes

Companies that use Cordlife

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Cordlife technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cordlife partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Stemlife Berhad (Malaysia)coreStrategic or Co-development PartnerMajority-owned subsidiary of Cordlife Group. Provides full stem cell banking services in Malaysia. Through this subsidiary, Cordlife has an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife.
  • Thai Stemlife (Thailand)coreStrategic or Co-development PartnerThailand's largest private cord blood bank. Cordlife has an indirect stake through its majority-owned subsidiary Stemlife Berhad in Malaysia.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Cordlife competitors and assessment

Company assessment

Emerging players

  • Cells4Life: UK-based private cord blood and tissue bank offering comparable collection, processing, and cryogenic storage services with a multi-country footprint.

Direct peers

  • Future Health Biobank: European-headquartered stem cell bank offering cord blood, cord tissue, and related banking services to families globally; closely comparable processing, storage, and consumer sales motion.
  • Stemlife Berhad: Cordlife's own majority-owned Malaysian subsidiary offering cord blood banking in Malaysia and Thailand (via Thai Stemlife) — a directly comparable private banking network in adjacent ASEAN markets.
  • StemCyte: US-based hybrid public-private cord blood bank providing both family banking and public registry services; comparable cryopreservation technology and clinical release track record.
  • Cryoviva (Thailand): Pan-Asian private cord blood bank with presence in Thailand, Singapore, India and other Asian markets; competes head-to-head with Cordlife for the same expectant-parent segment.

Broad incumbents

  • Cryo-Cell International: US-listed (NASDAQ: CCEL) cord blood and menstrual blood stem cell bank serving expectant parents; directly comparable business model of private/family cord blood banking with recurring storage revenue.
  • ViaCord (Revvity/PerkinElmer): One of the largest US private cord blood banks operated by Revvity; comparable consumer healthcare service targeting expectant parents with one-time processing plus annual storage fees.
  • Cord Blood Registry (CBR) by CooperCompanies: Long-established US private family cord blood bank under CooperSurgical (CooperCompanies); the clearest Western counterpart in scale, brand tenure, and stored-sample base.

Regional players

  • Singapore Cord Blood Bank: Non-profit public cord blood bank in Singapore; competes in the same Singapore market with a public-registry rather than private-storage model.
  • HealthBaby Hong Kong: Listed under Cordlife's Hong Kong navigation, HealthBaby is a major competing private cord blood bank in Hong Kong with overlapping expectant-parent customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Cordlife social profiles

Digital presence

Cordlife financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cordlife leadership team

Management profile

Number of profiles

Profiles1 record

Cordlife subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Cordlife funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cordlife M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cordlife

What does Cordlife do?

Cordlife provides private cord blood and cord lining/tissue stem cell banking services, collecting, processing, and cryogenically storing umbilical cord stem cells for potential future medical use. It also offers diagnostic services such as non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening for expectant families.

Is Cordlife a public or private company?

Cordlife is a public company. It is classified as public and is currently operating.

When was Cordlife founded?

Cordlife was founded in 2001. It employs 51 to 100 people.

Where is Cordlife based?

Cordlife is headquartered in Singapore, Singapore, in the Asia region.

How does Cordlife make money?

Three revenue lines are on record. Cord Blood Banking Services are the primary driver. The others are cord Lining/Tissue Banking and diagnostics Services.

Who are Cordlife's main competitors?

Cells4Life is listed as an emerging player. Direct peers are Future Health Biobank, Stemlife Berhad, StemCyte and Cryoviva (Thailand). Broad incumbents are Cryo-Cell International, ViaCord (Revvity/PerkinElmer) and Cord Blood Registry (CBR) by CooperCompanies. Regional players are Singapore Cord Blood Bank and HealthBaby Hong Kong.

Does Cordlife have an API?

No public API is recorded for Cordlife.

What industry is Cordlife in?

Cordlife's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue). Its NAICS code is 621991.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Business TimesStocks to watch: OCBC, Yangzijiang Shipbuilding, City Developments, First Reit, CordlifeSingapore-listed OCBC will lower interest rates on its 360 Account savings product to 4.45% from May 1, marking its first rate revision in 2026, while Yangzijiang Shipbuilding secured shipbuilding contracts for 22 vessels worth approximately US$980 million in Q1 2026. City Developments CEO Sherman Kwek received S$5.1 million in compensation for FY2025, a 70.8% increase from the prior year, and First Reit announced the divestment of its Indonesian portfolio for S$471.5 million. Cordlife's auditors PKF-CAP issued a disclaimer of opinion on its FY2025 financials, citing an inability to obtain sufficient appropriate audit evidence.The Business TimesCordlife secures one-year renewal for its cord-blood banking service licenceCordlife Group has received a one-year renewal for its cord-blood banking service licence in Singapore, which limits its activities to storing, transferring, or retrieving existing cord-blood units for clinical use. The company’s human tissue banking licence has also been renewed for two years, and it remains operational in other jurisdictions including Malaysia, Hong Kong, and India. Meanwhile, Cordlife faces a civil claim of at least S$5.45 million from clients over allegedly damaged cord-blood units.The Business TimesCordlife secures restricted licence renewal; seeks full trial for client claimsCordlife Group has secured a one-year renewal of its cord-blood banking service licence from Jan 14, 2026 to Jan 13, 2027, but remains under strict regulatory curbs that prohibit collecting, testing, or storing any new cord-blood units, with its scope limited to storing, transferring, or retrieving existing units for clinical use. The company faces client claims of at least S$5.45 million in damages for 109 allegedly damaged cord-blood units and has applied to convert these claims into an "originating claim" for a full trial process. The company's human tissue banking service licence was also renewed for two years, while its operations in Malaysia, Hong Kong, and India remain fully operational.The Business TimesStocks to watch: Keppel Reit, Olam Group, F&N, Centurion, CordlifeKeppel Reit's units will be listed on the Singapore Exchange following a successful acceptances in its preferential offering. Olam Group is progressing with the sale of its remaining stake in Arise P&L. Frasers and Neave priced S$125 million in fixed-rate notes, and Centurion completed development and divestment of a property. Cordlife renewed its license for cord blood banking for one year.The Business TimesStocks to watch: Cordlife, DFI Retail Group, SingLand, Tuan Sing, Vibrant GroupCordlife announced it faces claims of at least S$5.45 million in damages from clients regarding 109 stored cord-blood units, a development the board warned would negatively impact its financials for the year ending December 31. The company's shares declined by 2 percent to S$0.146 following the announcement of potential liabilities.The Business TimesCordlife faces S$5.45 million civil claim from clients over damaged cord blood unitsCordlife Group is facing a civil claim of at least S$5.45 million from clients over 109 damaged cord blood units stored in tanks labelled as high risk. The company warned that paying these damages would negatively impact its financials for the year ending December 31, following previous operational lapses and regulatory scrutiny by Singapore's Ministry of Health.The Business TimesStocks to watch: UOB, Lendlease Reit, IHH Healthcare, CordlifeUOB secured a S$17.7 million court award in the Lippo Marina Collection lawsuit after the judge determined the bank failed to fully mitigate its losses, falling short of its initial S$92 million claim. Meanwhile, IHH Healthcare reported a 15% increase in third-quarter net profit and declared an interim dividend, while Lendlease REIT completed the S$234.3 million acquisition of a stake in PLQ Mall.The Business TimesMOH orders Cordlife to stop collecting cord blood; company calls for trading haltThe Ministry of Health (MOH) has ordered Cordlife to stop collecting, testing, processing, and storing new cord blood effective November 26, following regulatory concerns. Cordlife is allowed only to manage existing cord-blood units while under this suspension, which will remain in effect even if the company's license is renewed in January 2026, until it meets regulatory standards. The MOH's actions were prompted by Cordlife's inadequate responses to previous audits regarding its cord-blood banking services.The Straits TimesSGX listings rise: Singapore preferred IPO venueFour companies filed preliminary IPO documents on the Singapore Exchange last week, with Singapore reporting seven mainboard listings so far in 2025, highlighting renewed investor appetite in the local stock market. Singapore has risen to ninth place on Bloomberg's ranking of world top IPO venues, surpassing London which slipped to 23rd, as analysts point to improved liquidity and investor confidence beyond the 30 blue-chip Straits Times Index stocks. The broader market also saw notable movers including Yangzijiang Shipbuilding recovering from a contract cancellation, Singtel addressing an Optus network outage, and Cordlife Group facing a license suspension by Singapore's Ministry of Health.YahooTop Stock Market Highlights of the Week: Coliwoo IPO Filing, Cordlife Suspension and Electronic Arts AcquisitionElectronic Arts agreed to the largest leveraged buyout ever at US$55 billion, while Singapore's Coliwoo filed for a mainboard listing on the SGX as part of LHN Group's co-living expansion strategy targeting 10,000 rooms by 2030. Cordlife Group faces a potential one-year suspension of its cord blood banking services following compliance failures revealed in MOH audits, and Mandarin Oriental entered advanced negotiations with Alibaba for a HK$7 billion deal at its Causeway Bay property.